We recently published 10 Big Names With Explosive Growth. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals jumped by 16.44 percent on ...

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Biotech Recursion announced a definitive merger agreement with drug design and development company Exscientia on Thursday morning. The combined company, which is expected to yield annual synergies of ...

We recently published 10 Big Names Beating Wall Street at its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Monday. Recursion Pharmaceuticals soared by 13.99 ...

Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.75, demonstrating a -5.89% change from the preceding ...